SEC Tracker
Get the app

Altimmune ALT

Altimmune Announces First Quarter 2025 Financial Results and Business Update

Form
8-K
Filed
Importance
Routine
  • Signs a material agreement (1.01)
  • Reports quarterly results (2.02)
  • Takes on a new financial obligation (2.03)
  • Makes a Regulation FD disclosure (7.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Altimmune files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Rigel Pharmaceuticals RIGL public float $332M, Jun 30, 2025
  2. Amarin AMRN public float $335M, Jun 30, 2025
  3. Nektar Therapeutics NKTR public float $318M, Jun 30, 2025
  4. Northwest Biotherapeutics NWBO public float $340M, Jun 30, 2025
  5. Emergent BioSolutions EBS public float $343M, Jun 30, 2025